bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
2.230
-0.070 (-3.04%)
At close: Apr 24, 2026, 4:00 PM EDT
2.240
+0.010 (0.45%)
After-hours: Apr 24, 2026, 7:57 PM EDT
bioAffinity Technologies Employees
bioAffinity Technologies had 57 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
57
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$108,105
Profits / Employee
-$261,575
Market Cap
10.02M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 57 | 0 | - |
| Dec 31, 2024 | 57 | -18 | -24.00% |
| Dec 31, 2023 | 75 | 61 | 435.71% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Inotiv | 2,046 |
| MDxHealth | 364 |
| Biodesix | 334 |
| XWELL | 280 |
| Exagen | 220 |
| Precipio | 71 |
| Advanced Biomed | 31 |
| Mainz Biomed | 26 |
BIAF News
- 11 days ago - New Case Study: bioAffinity Technologies' CyPath® Lung Diagnostic Supports Physician's Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy - Business Wire
- 16 days ago - bioAffinity Technologies Transcript: Status update - Transcripts
- 18 days ago - bioAffinity Technologies' CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16 - Business Wire
- 24 days ago - bioAffinity Technologies' CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026 - Business Wire
- 4 weeks ago - bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice - Business Wire
- 5 weeks ago - New Case Study: bioAffinity Technologies' CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures - Business Wire
- 6 weeks ago - bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth - Benzinga
- 6 weeks ago - bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung - Business Wire